April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
The study concluded that Frontal fibrosing alopecia can affect younger people, is often missed in men, and may be autoimmune-related.
October 2025 in “Pharmaceuticals” Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
5 citations
,
July 2003 in “Drug Development Research” Fluridil promotes hair growth safely and effectively for androgenetic alopecia.
February 2024 in “Skin research and technology” The research suggests that immune cells and a specific type of cell death called ferroptosis are involved in Frontal fibrosis alopecia.
1 citations
,
October 2008 in “Expert Review of Dermatology” Frontal Fibrosing Alopecia is a slowly progressing hair loss condition, likely underdiagnosed, with ineffective treatments, needing more research to understand it fully.
6 citations
,
July 2004 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Frontal fibrosing alopecia in postmenopausal women can be managed with early treatment using corticosteroids to stop hair loss.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
24 citations
,
January 2012 in “Indian Journal of Dermatology, Venereology and Leprology” Diffuse alopecia areata involves more inflammation and higher allergy-related antibodies than patchy types.
49 citations
,
January 2003 in “Clinical and Experimental Dermatology” The document concludes that post-menopausal frontal fibrosing alopecia is a poorly understood condition that does not respond well to common treatments.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
July 2024 in “Journal of Investigative Dermatology” Linalool in fragrances may harm hair follicles and contribute to hair loss.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
16 citations
,
December 2015 in “Journal of Investigative Dermatology” Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
19 citations
,
March 1997 in “Journal of Cutaneous Pathology” Alopecia areata involves specific T-cells, unlike androgenetic alopecia.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
May 2026 in “Acta Dermato Venereologica” Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.
December 2016 in “Anales del sistema sanitario de Navarra” Frontal fibrosing alopecia is increasing, especially in postmenopausal women, and treatment with finasteride can improve it.
44 citations
,
November 2016 in “Journal of The American Academy of Dermatology” The updated SALT II tool offers a more precise way to measure scalp hair loss.
June 2026 in “Frontiers in Medicine” The excimer laser is a promising and safe treatment for frontal fibrosing alopecia.
11 citations
,
May 2023 in “Journal of Cutaneous Medicine and Surgery” Plasma Rich in Growth Factors may help reduce hair loss in Frontal Fibrosing Alopecia.
2 citations
,
May 2025 in “Diagnostics” ATR-FTIR spectroscopy could help monitor alopecia areata treatment response non-invasively.
April 2026 in “Dermatology Practical & Conceptual” AMT may be more effective than finasteride for hair growth in androgenetic alopecia.
November 2021 in “CRC Press eBooks” Anagen effluvium is a reversible condition causing sudden hair loss, often due to chemotherapy or head radiation.
13 citations
,
March 2014 in “Journal of Clinical Laboratory Analysis” Higher MIF levels in alopecia areata patients suggest it could be a treatment target and disease predictor.
6 citations
,
January 2024 in “International Journal of Dermatology” Monoclonal antibodies are often linked to alopecia areata cases.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
489 citations
,
November 2021 in “Signal Transduction and Targeted Therapy” The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.